Beneficial effects of blueberry supplementation on the components of metabolic syndrome: a systematic review and meta-analysis.

Metabolic syndrome (MetS) is a combination of interconnected disorders that puts a heavy burden on society. This study investigated the impact of blueberry (BB) supplementation on components of MetS. A systematic search for studies in Embase, Science Direct, Cochrane and PubMed was done. Interventions for at least 2 weeks and studies which investigated the effects of BB on components of MetS in human subjects were included. 25 studies were eligible for inclusion in the review. 21 studies were included in the meta-analysis and the remaining 4 studies in the systematic review. The time range of the assessed studies was from 2007 to 2021. The results of the meta-analysis demonstrated that BB had no significant effect on waist circumference, body mass index (BMI), glycated hemoglobin (HbA1C), glucose level and homeostatic model assessment for insulin resistance (HOMA-IR); however, studies showed a significant improvement in systolic and diastolic blood pressure, triglycerides, total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and insulin levels. In conclusion, the data in this meta-analysis show that BB supplementation is a beneficial option for the management of MetS in humans.

The effect of cumin supplementation on metabolic profiles in patients with metabolic syndrome: A randomized, triple blind, placebo-controlled clinical trial.

Metabolic syndrome (MetS) is a cluster of interconnected serious disorders, which is a major health problem whose prevalence is increasing. Oxidative stress and inflammation contribute to the disease pathogenesis and its complications. The present study aimed to investigate the effect of Cuminum cyminum L. (which has antioxidant and anti-inflammatory properties) essential oil (CuEO) supplementation on inflammatory and antioxidant status in patients with MetS. In this clinical trial, 56 patients with MetS aged 18-60 years received either 75-mg CuEO or placebo soft gel, thrice daily, for 8 weeks. Data on anthropometric parameters, food consumption, tumor necrosis factor alpha, high-sensitivity C-reactive protein, superoxide dismutase (SOD), glutathione peroxidase, catalase, total antioxidant capacity (TAC), and malondialdehyde (MDA) were assessed at the beginning and at the end of the study. Compared with the placebo group, CuEO increased SOD (149.17; 95% CI, [67.93, 230.42]), TAC (0.24; 95% CI, [0.09, 0.38]) and decreased MDA (-0.36; 95% CI, [-0.66, 0.06]), (p < 0.01). In within-group analysis, CuEO led to 13.3% decrease in MDA and 6.7% increase in TAC levels (p < 0.04). The results indicated that CuEO supplementation can improve some antioxidative indices, as SOD and TAC, while decreasing MDA in patients with MetS.